Dupilumab Provides Significant Clinical Benefit in a Phase 3 Trial in Adolescents with Uncontrolled Atopic Dermatitis Irrespective of Prior Systemic Immunosuppressant Use

Authors :: Kangmo Ahn
Ana Paula Castro
Alan D. Irvine
Gaëlle Bégo-Le-Bagousse
Marjolein S. de Bruin-Weller
Mette Deleuran
Eulalia Baselga
Danielle Marcoux
Jingdong Chao
Ashish Bansal
Ana B. Rossi
Source :: Acta Dermato-Venereologica, Vol 101, Iss 7, p adv00504 (2021), Deleuran, M, Marcoux, D, DE BRUIN-WELLER, M S, Irvine, A D, Baselga, E, Ahn, K, Castro, A P, Bansal, A, Chao, J, Bégo-Le Bagousse, G & Rossi, A B 2021, ' Dupilumab provides significant clinical benefit in a phase 3 trial in adolescents with uncontrolled atopic dermatitis irrespective of prior systemic immunosuppressant use ', Acta Dermato-Venereologica, vol. 101, no. July, adv00504 . https://doi.org/10.2340/00015555-3848
Publication Year :: 2021
Abstract: is missing (Short communication)

Full Text Access

Tools